CN116528696A - 高纯度β烟酰胺单核苷酸（NMN）及其制造方法 - Google Patents

高纯度β烟酰胺单核苷酸（NMN）及其制造方法 Download PDF

Info

Publication number
CN116528696A
CN116528696A CN202180079830.6A CN202180079830A CN116528696A CN 116528696 A CN116528696 A CN 116528696A CN 202180079830 A CN202180079830 A CN 202180079830A CN 116528696 A CN116528696 A CN 116528696A
Authority
CN
China
Prior art keywords
purity
nmn
present
βnmn
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079830.6A
Other languages
English (en)
Chinese (zh)
Inventor
田中经丸
田中惠
平松隆司
岛村大藏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Future Laboratory Bioscience Co ltd
Original Assignee
Future Laboratory Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Future Laboratory Bioscience Co ltd filed Critical Future Laboratory Bioscience Co ltd
Publication of CN116528696A publication Critical patent/CN116528696A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02007—Adenine phosphoribosyltransferase (2.4.2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/06—Diphosphotransferases (2.7.6)
    • C12Y207/06001—Ribose-phosphate diphosphokinase (2.7.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07001—Nicotinamide-nucleotide adenylyltransferase (2.7.7.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02004—AMP nucleosidase (3.2.2.4)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
CN202180079830.6A 2020-11-27 2021-11-26 高纯度β烟酰胺单核苷酸（NMN）及其制造方法 Pending CN116528696A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-197381 2020-11-27
JP2020197381 2020-11-27
PCT/JP2021/043333 WO2022114105A1 (ja) 2020-11-27 2021-11-26 高純度βニコチンアミドモノヌクレオチド（ＮＭＮ）及びその製造方法

Publications (1)

Publication Number Publication Date
CN116528696A true CN116528696A (zh) 2023-08-01

Family

ID=81754422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079830.6A Pending CN116528696A (zh) 2020-11-27 2021-11-26 高纯度β烟酰胺单核苷酸（NMN）及其制造方法

Country Status (6)

Country Link
US (1) US20230416291A1 (https=)
EP (1) EP4253396A4 (https=)
JP (1) JPWO2022114105A1 (https=)
KR (1) KR20230113770A9 (https=)
CN (1) CN116528696A (https=)
WO (1) WO2022114105A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183464A (ja) * 2022-11-04 2025-12-17 ミライラボバイオサイエンス株式会社 イヌの腸内細菌叢改善用剤
JPWO2024225432A1 (https=) * 2023-04-28 2024-10-31

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN108026132A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种烟酰胺单核苷酸的纯化方法
CN108026517A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种烟酰胺磷酸核糖转移酶突变体及其应用
CN108530504A (zh) * 2017-03-02 2018-09-14 江苏康缘药业股份有限公司 一种化合物及其制备方法和应用
CN108530505A (zh) * 2017-03-02 2018-09-14 江苏康缘药业股份有限公司 一种黄酮苷类化合物及其制备方法和应用
CN108697722A (zh) * 2015-10-02 2018-10-23 麦德龙国际生物科技有限责任公司 β-烟酰胺单核苷酸的晶体形式
CN110483601A (zh) * 2019-08-12 2019-11-22 上海龙翔生物医药开发有限公司 制备β-烟酸胺单核苷酸的方法及其应用
CN110845548A (zh) * 2019-11-22 2020-02-28 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法
CN111187759A (zh) * 2020-01-19 2020-05-22 杭州唯泰生物药业有限公司 用于制备烟酰胺单核苷酸的酶组合物及酶法制备烟酰胺单核苷酸的方法
CN111377983A (zh) * 2020-03-26 2020-07-07 音芙医药科技(上海)有限公司 一种β-烟酰胺单核苷酸的制备方法
CN111568913A (zh) * 2020-05-18 2020-08-25 厦门医学院 黄酮c-苷类化合物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2893615B1 (fr) * 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
ES2333539T3 (es) * 2006-04-21 2010-02-23 Cellzome Limited Derivados de terfenilo para el tratamiento de la enfermedad de alzheimer.
JP2014527955A (ja) * 2011-06-29 2014-10-23 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 糖質コルチコイド介在性障害の処置のための、インダゾリルアミド誘導体の結晶形
WO2015069860A1 (en) 2013-11-06 2015-05-14 President And Fellows Of Harvard College Biological production of nad precursors and analogs
KR20150069860A (ko) 2013-12-16 2015-06-24 송석록 낚시용 자석 봉돌
DE102016105985A1 (de) 2016-04-01 2017-10-05 Wipotec Wiege- Und Positioniersysteme Gmbh Verfahren und Vorrichtung zur Laserbearbeitung
WO2017185549A1 (zh) 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697722A (zh) * 2015-10-02 2018-10-23 麦德龙国际生物科技有限责任公司 β-烟酰胺单核苷酸的晶体形式
CN108026132A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种烟酰胺单核苷酸的纯化方法
CN108026517A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种烟酰胺磷酸核糖转移酶突变体及其应用
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN108530504A (zh) * 2017-03-02 2018-09-14 江苏康缘药业股份有限公司 一种化合物及其制备方法和应用
CN108530505A (zh) * 2017-03-02 2018-09-14 江苏康缘药业股份有限公司 一种黄酮苷类化合物及其制备方法和应用
CN110483601A (zh) * 2019-08-12 2019-11-22 上海龙翔生物医药开发有限公司 制备β-烟酸胺单核苷酸的方法及其应用
CN110845548A (zh) * 2019-11-22 2020-02-28 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法
CN111187759A (zh) * 2020-01-19 2020-05-22 杭州唯泰生物药业有限公司 用于制备烟酰胺单核苷酸的酶组合物及酶法制备烟酰胺单核苷酸的方法
CN111377983A (zh) * 2020-03-26 2020-07-07 音芙医药科技(上海)有限公司 一种β-烟酰胺单核苷酸的制备方法
CN111568913A (zh) * 2020-05-18 2020-08-25 厦门医学院 黄酮c-苷类化合物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宋航主编: "《制药分离工程》", 31 August 2011, 华东理工大学出版社, pages: 241 - 243 *

Also Published As

Publication number Publication date
EP4253396A4 (en) 2024-09-11
KR20230113770A9 (ko) 2024-03-25
US20230416291A1 (en) 2023-12-28
KR20230113770A (ko) 2023-08-01
EP4253396A1 (en) 2023-10-04
WO2022114105A1 (ja) 2022-06-02
JPWO2022114105A1 (https=) 2022-06-02

Similar Documents

Publication Publication Date Title
Ciardo et al. Topical review: Neurologic aspects of adenylosuccinate lyase deficiency
EP2975028B1 (en) Pyrazole-amide compound and medicinal uses therefor
CN116528696A (zh) 高纯度β烟酰胺单核苷酸（NMN）及其制造方法
US20160354332A1 (en) Therapeutic strategies for treating mitochondrial disorders
JP7658528B2 (ja) 還元型β－ニコチンアミドモノヌクレオチド又はその薬理学的に許容される塩からなる還元型β－ニコチンアミドアデニンジヌクレオチド前駆体化合物を含む組成物、並びにその品質評価方法および酵素反応性の判定方法
EP3613731A1 (en) Applications of spermidine and its derivative
CA2601716C (en) Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
EP3199154A1 (en) Novel life-prolonging agent, life-prolonging method making use of same, novel dual oxidase activator, method for activating dual oxidase, manufacture of life-prolonging agent, and manufacture of dual oxidase activator
Zhang et al. Emerging strategies, applications and challenges of targeting NAD+ in the clinic
EP3613416B1 (en) Applications of spermine and its derivative in preparation of antitumor drug
EP2647637B1 (en) Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
US20100234433A1 (en) Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
EP1014808A1 (en) Fatty acids as a diet supplement
WO2015164622A2 (en) Analogs of n-acetylglucosamine and uses thereof
JP2025505975A (ja) ニコチネート及びニコチンアミドリボシドベースの化合物及びその誘導体
Salerno et al. Effect of D-ribose administration to a patient with inherited deficit of adenylosuccinase
US20230295211A1 (en) Methods of producing crystalline beta nicotinamide riboside triacetate chloride
WO2022022472A1 (zh) 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型
US8778996B2 (en) Method of treating a human being for a class of neurological defects and seizure disorders
Van den Berghe et al. Purine nucleotide cycle, molecular defects and therapy
Nyhan et al. Argininemia
JP5663731B2 (ja) Ｄｎａ合成酵素の阻害剤
Van den Berghe et al. UCL 7539, B-1200 Brussels, Belgium
KR20220057566A (ko) 미토콘드리아 dna 고갈 장애의 치료
CN117924396A (zh) 一种胞磷胆碱钠杂质及其制备方法、分离检测方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095062

Country of ref document: HK